Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
Background. Docetaxel (DOC) was the first regimen that increased the survival and became the standard-of-care in patients with metastatic castration-resistant prostate cancer (mCRPC). However, it is unclear whether switching to second-line chemotherapy or optimal sequencing of cabazitaxel (CBZ) ensu...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1155/2021/8824140 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561782733930496 |
|---|---|
| author | Seiichi Kato Manabu Takai Koji Iinuma Shota Fujimoto Masahiro Nakano Takashi Ishida Masahiro Uno Masayoshi Tamaki Mitsuhiro Taniguchi Hisao Komeda Yoshito Takahashi Takuya Koie |
| author_facet | Seiichi Kato Manabu Takai Koji Iinuma Shota Fujimoto Masahiro Nakano Takashi Ishida Masahiro Uno Masayoshi Tamaki Mitsuhiro Taniguchi Hisao Komeda Yoshito Takahashi Takuya Koie |
| author_sort | Seiichi Kato |
| collection | DOAJ |
| description | Background. Docetaxel (DOC) was the first regimen that increased the survival and became the standard-of-care in patients with metastatic castration-resistant prostate cancer (mCRPC). However, it is unclear whether switching to second-line chemotherapy or optimal sequencing of cabazitaxel (CBZ) ensures better clinical outcomes. We aimed to evaluate the efficacy of sequential therapy with DOC and CBZ and the effect of the number of prior DOC cycles on oncological outcomes in patients with mCRPC. Methods. We retrospectively included 46 mCRPC patients who received DOC followed by CBZ at quaternary hospitals in Japan between February 2015 and March 2019. Participants received intravenous DOC (40–75 mg/m2) every 3–4 weeks; CBZ (15–25 mg/m2) was administered every 3–4 weeks. Androgen-deprivation therapy and prednisolone 5 mg (twice daily) were administered throughout both regimens. The primary endpoints were overall (OS) and progression-free survival (PFS). The secondary endpoints were the rates of ≥30% and ≥50% reduction in prostate-specific antigen (PSA) levels at chemotherapy initiation. Results. Participants were divided into two groups according to DOC cycles (Groups A and B: ≤6 and ≥7 DOC cycles, respectively). The rates of ≥30% and ≥50% reduction in PSA levels were higher in Group B than in Group A, but there were no significant differences in both groups. Median OS in Groups A and B was 12.7 and 71.0 months, respectively P<0.001; median PFS in Groups A and B was 3 and 12 months, respectively P<0.001. Conclusions. Administration of ≥7 cycles of DOC followed by CBZ may improve oncological outcomes in patients with mCRPC. |
| format | Article |
| id | doaj-art-955ba04ad759460bb378a81a0b2ee11f |
| institution | Kabale University |
| issn | 2356-6140 1537-744X |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-955ba04ad759460bb378a81a0b2ee11f2025-02-03T01:24:12ZengWileyThe Scientific World Journal2356-61401537-744X2021-01-01202110.1155/2021/88241408824140Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate CancerSeiichi Kato0Manabu Takai1Koji Iinuma2Shota Fujimoto3Masahiro Nakano4Takashi Ishida5Masahiro Uno6Masayoshi Tamaki7Mitsuhiro Taniguchi8Hisao Komeda9Yoshito Takahashi10Takuya Koie11Department of Urology, Ogaki Municipal Hospital, 4-86 Minaminokawacho, Ogaki 503-8502, JapanDepartment of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, JapanDepartment of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, JapanDepartment of Urology, Gifu Municipal Hospital, 7-1 Kashimacho, Gifu 500-8513, JapanDepartment of Urology, Gifu Prefectural General Medical Center, 4-6-1 Noishiki, Gifu 500-8717, JapanDepartment of Urology, Ogaki Municipal Hospital, 4-86 Minaminokawacho, Ogaki 503-8502, JapanDepartment of Urology, Ogaki Municipal Hospital, 4-86 Minaminokawacho, Ogaki 503-8502, JapanDepartment of Urology, Gifu Municipal Hospital, 7-1 Kashimacho, Gifu 500-8513, JapanDepartment of Urology, Gifu Prefectural General Medical Center, 4-6-1 Noishiki, Gifu 500-8717, JapanDepartment of Urology, Gifu Municipal Hospital, 7-1 Kashimacho, Gifu 500-8513, JapanDepartment of Urology, Gifu Prefectural General Medical Center, 4-6-1 Noishiki, Gifu 500-8717, JapanDepartment of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, JapanBackground. Docetaxel (DOC) was the first regimen that increased the survival and became the standard-of-care in patients with metastatic castration-resistant prostate cancer (mCRPC). However, it is unclear whether switching to second-line chemotherapy or optimal sequencing of cabazitaxel (CBZ) ensures better clinical outcomes. We aimed to evaluate the efficacy of sequential therapy with DOC and CBZ and the effect of the number of prior DOC cycles on oncological outcomes in patients with mCRPC. Methods. We retrospectively included 46 mCRPC patients who received DOC followed by CBZ at quaternary hospitals in Japan between February 2015 and March 2019. Participants received intravenous DOC (40–75 mg/m2) every 3–4 weeks; CBZ (15–25 mg/m2) was administered every 3–4 weeks. Androgen-deprivation therapy and prednisolone 5 mg (twice daily) were administered throughout both regimens. The primary endpoints were overall (OS) and progression-free survival (PFS). The secondary endpoints were the rates of ≥30% and ≥50% reduction in prostate-specific antigen (PSA) levels at chemotherapy initiation. Results. Participants were divided into two groups according to DOC cycles (Groups A and B: ≤6 and ≥7 DOC cycles, respectively). The rates of ≥30% and ≥50% reduction in PSA levels were higher in Group B than in Group A, but there were no significant differences in both groups. Median OS in Groups A and B was 12.7 and 71.0 months, respectively P<0.001; median PFS in Groups A and B was 3 and 12 months, respectively P<0.001. Conclusions. Administration of ≥7 cycles of DOC followed by CBZ may improve oncological outcomes in patients with mCRPC.http://dx.doi.org/10.1155/2021/8824140 |
| spellingShingle | Seiichi Kato Manabu Takai Koji Iinuma Shota Fujimoto Masahiro Nakano Takashi Ishida Masahiro Uno Masayoshi Tamaki Mitsuhiro Taniguchi Hisao Komeda Yoshito Takahashi Takuya Koie Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer The Scientific World Journal |
| title | Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer |
| title_full | Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer |
| title_fullStr | Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer |
| title_full_unstemmed | Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer |
| title_short | Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer |
| title_sort | sequential docetaxel in ≥7 cycles followed by cabazitaxel improves oncological outcomes in patients with metastatic castration resistant prostate cancer |
| url | http://dx.doi.org/10.1155/2021/8824140 |
| work_keys_str_mv | AT seiichikato sequentialdocetaxelin7cyclesfollowedbycabazitaxelimprovesoncologicaloutcomesinpatientswithmetastaticcastrationresistantprostatecancer AT manabutakai sequentialdocetaxelin7cyclesfollowedbycabazitaxelimprovesoncologicaloutcomesinpatientswithmetastaticcastrationresistantprostatecancer AT kojiiinuma sequentialdocetaxelin7cyclesfollowedbycabazitaxelimprovesoncologicaloutcomesinpatientswithmetastaticcastrationresistantprostatecancer AT shotafujimoto sequentialdocetaxelin7cyclesfollowedbycabazitaxelimprovesoncologicaloutcomesinpatientswithmetastaticcastrationresistantprostatecancer AT masahironakano sequentialdocetaxelin7cyclesfollowedbycabazitaxelimprovesoncologicaloutcomesinpatientswithmetastaticcastrationresistantprostatecancer AT takashiishida sequentialdocetaxelin7cyclesfollowedbycabazitaxelimprovesoncologicaloutcomesinpatientswithmetastaticcastrationresistantprostatecancer AT masahirouno sequentialdocetaxelin7cyclesfollowedbycabazitaxelimprovesoncologicaloutcomesinpatientswithmetastaticcastrationresistantprostatecancer AT masayoshitamaki sequentialdocetaxelin7cyclesfollowedbycabazitaxelimprovesoncologicaloutcomesinpatientswithmetastaticcastrationresistantprostatecancer AT mitsuhirotaniguchi sequentialdocetaxelin7cyclesfollowedbycabazitaxelimprovesoncologicaloutcomesinpatientswithmetastaticcastrationresistantprostatecancer AT hisaokomeda sequentialdocetaxelin7cyclesfollowedbycabazitaxelimprovesoncologicaloutcomesinpatientswithmetastaticcastrationresistantprostatecancer AT yoshitotakahashi sequentialdocetaxelin7cyclesfollowedbycabazitaxelimprovesoncologicaloutcomesinpatientswithmetastaticcastrationresistantprostatecancer AT takuyakoie sequentialdocetaxelin7cyclesfollowedbycabazitaxelimprovesoncologicaloutcomesinpatientswithmetastaticcastrationresistantprostatecancer |